Head to Head Review: Hyperfine (NASDAQ:HYPR) vs. Vasamed (OTCMKTS:VSMD)

Hyperfine (NASDAQ:HYPR) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Analyst Ratings

This is a breakdown of recent recommendations for Hyperfine and Vasamed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	1	2	0	2.25
Vasamed	0	0	0	0	0.00

Hyperfine presently has a consensus price target of $1.28, suggesting a potential upside of 11.59%. Given Hyperfine’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Hyperfine is more favorable than Vasamed.

Institutional & Insider Ownership

15.0% of Hyperfine shares are held by institutional investors. 31.0% of Hyperfine shares are held by company insiders. Comparatively, 8.0% of Vasamed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Hyperfine and Vasamed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$12.89 million	7.01	-$40.72 million	($0.52)	-2.21
Vasamed	N/A	N/A	N/A	N/A	N/A

Vasamed has lower revenue, but higher earnings than Hyperfine.

Volatility and Risk

Hyperfine has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Vasamed has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Profitability

This table compares Hyperfine and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-378.17%	-88.97%	-71.90%
Vasamed	N/A	N/A	N/A

Summary

Hyperfine beats Vasamed on 7 of the 10 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.